22:49 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

DCVax-L: Ph III ongoing

Northwest Biotherapeutics said FDA lifted the partial clinical hold on a double-blind, placebo-controlled, international Phase III trial evaluating intradermal DCVax-L given at days 0, 10 and 20 and weeks 8, 16, 32, 48, 72, 96...
22:00 , Jan 5, 2017 |  BC Week In Review  |  Clinical News

DCVax-L: Ph III ongoing

Northwest Biotherapeutics said it will not enroll the last 17 patients of a planned 348 into a double-blind, placebo-controlled, international Phase III trial of intradermal DCVax-L. Last year, FDA placed a partial hold on further...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

DCVax-Brain: Clinical trial data

Data from 51 evaluable patients with newly diagnosed GBM showed that DCVax-L led to a median OS of 18.3 months, with 15 patients living for >2 years and 12 patients still alive. In 20 rapid...
01:50 , Mar 28, 2015 |  BC Extra  |  Clinical News

Northwest gains on GBM survival data

Northwest Biotherapeutics Inc. (NASDAQ:NWBO) reported data from glioblastoma multiforme (GBM) patients who were ineligible for enrollment in the company's ongoing Phase III trial of DCVax-Brain ( DCVax-L ), and instead were treated in a separate...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

DCVax-L regulatory update

The U.K.'s Department of Health granted DCVax-L from Northwest Biotherapeutics promising innovative medicine (PIM) designation to treat all malignant gliomas, making it the first medicine to receive the designation. The designation is given to products...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

DCVax-L: Phase III ongoing

Northwest Biotherapeutics said a DSMB recommended continuation of a double-blind, international Phase III trial evaluating DCVax-L in 312 GBM patients based on a review of safety data. Patients with newly diagnosed GBM indicated for surgery...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

DCVax-L regulatory update

Northwest Biotherapeutics said Germany's Paul Ehrlich Institute (PEI) approved a "hospital exemption" early access program for DCVax- L to treat newly diagnosed and recurrent glioma. According to the company, Germany's Institute for the Hospital Remuneration...
00:55 , Nov 21, 2013 |  BC Extra  |  Financial News

Northwest raises $23.5 million in follow-on

Northwest Biotherapeutics Inc. (NASDAQ:NWBO) raised $23.5 million through the sale of 4.9 million units at $4.80 in a follow-on underwritten by Oppenheimer. Each unit comprises a share and a five-year warrant to purchase 0.5 shares,...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

DCVax-L: Phase III ongoing

Northwest Biotherapeutics said the U.K.'s National Institute for Health Research (NIHR) "adopted" the biotech's double-blind, international Phase III trial of DCVax-L in up to 300 patients with newly diagnosed GBM as a national priority trial...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Northwest Biotherapeutics cancer news

Northwest Biotherapeutics said in its 2012 earnings that last May it received a $5.5 million grant from the German government. The grant, which the company plans to start drawing upon this quarter, provides matching funds...